In 2024, the annual spending on public healthcare in the United Kingdom (UK) accounted for *** percent of GDP. This is an increase from *** percent in 2023. Total spending on health in the UK In total, approximately *** billion British pounds were spent on healthcare in the UK in 2024. Although, spending as a share of GDP decreased from 2009 to 2019, the total spending on health has continued to increase. Broken down by function, the UK government spent *** billion pounds on curative/rehabilitative care. Performance of the NHS in the UK Waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that ** percent of patients should be seen within * hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.

Healthcare spending in the United Kingdom (UK) as a share of the gross domestic product (GDP) has increased since 1990, when it was 5.1 percent. By 2024, healthcare expenditure in the UK amounted to 11.1 percent of the GDP. Health expenditure in the UK compared to Europe  In comparison to other European countries in 2023, the UK ranked fifth highest in terms of healthcare spending as a share of the GDP. Top of the list was Germany, which spent 12.3 percent of its GDP on healthcare in this year. This was followed by Austria and Switzerland, which spent 11.8 percent and 11.7 percent on health, respectively. Performance of the NHS in the UK Waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.   

United Kingdom UK: Current Health Expenditure: % of GDP data was reported at 9.877 % in 2015. This records an increase from the previous number of 9.799 % for 2014. United Kingdom UK: Current Health Expenditure: % of GDP data is updated yearly, averaging 7.615 % from Dec 2000 (Median) to 2015, with 16 observations. The data reached an all-time high of 9.877 % in 2015 and a record low of 6.012 % in 2000. United Kingdom UK: Current Health Expenditure: % of GDP data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s UK – Table UK.World Bank: Health Statistics. Level of current health expenditure expressed as a percentage of GDP. Estimates of current health expenditures include healthcare goods and services consumed during each year. This indicator does not include capital health expenditures such as buildings, machinery, IT and stocks of vaccines for emergency or outbreaks.; ; World Health Organization Global Health Expenditure database (http://apps.who.int/nha/database).; Weighted average;

Healthcare spending in the United Kingdom stood at 317 billion British pounds in 2024. When looking at real healthcare expenditure*, spending already exceeded this amount in 2021, where it reached 324 billion British pounds in 2024 prices. Health expenditure in the UK compared to Europe In 2024, the UK spent almost 11 percent of its GDP on healthcare. In comparison to other European countries, this ranked the UK fifth in terms of health expenditure. At the top of the list was Switzerland, which spent 12 percent of its GDP on healthcare that year.  Performance of the NHS in the UK Waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.

Total healthcare expenditure in the UK as a percentage of GDP.

The healthcare spending growth rate in the United Kingdom (UK) has experienced fluctuations since 1998. Then, the healthcare spending growth rate was 6.5 percent and by 2020 the healthcare spending growth was highest at 13.2 percent. 2002 saw the second highest healthcare spending growth rate at 9.9 percent. In 2023, the growth rate was 5.9 percent, a significant increase from the preceding year. Health expenditure in the UK compared to Europe In 2023, the UK spent just 10.9 percent of its GDP on healthcare. In comparison to other European countries, this ranked the UK fifth in terms of health expenditure in 2023. Top of the list was Switzerland, which spent 12 percent of its GDP on healthcare in this year. Consequences from low spending growth? The majority of surveyed individuals in the UK, regard the NHS as a world class health service and remain happy with the high level of care provided by the organization. Although waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.

In 2022, spending on private/voluntary healthcare accounted for **** percent of GDP. The share has generally increased since 2000 when private/voluntary healthcare spending was just **** percent of GDP. This statistic displays the annual spending on private (voluntary) healthcare as a share of GDP in the United Kingdom from 2000 to 2022.

The government of the United Kingdom spent 241.8 billion British pounds on health in 2024/25, compared with 222 billion pounds in the previous financial year.

Healthcare spending in the United Kingdom (UK) in both sectors has increased since 1997, although spending in the public sector has increased at a faster rate. By 2018, public healthcare expenditure in the UK stood at to 149.5 billion British pounds, compared to 34.5 billion British pounds in the private sector.

Health expenditure in the UK compared to Europe 

In 2019, the UK spent just over ten percent of its GDP on healthcare. In comparison to other European countries, this ranked the UK seventh in terms of health expenditure in 2019. Top of the list was Switzerland, which spent 12.1 percent of its’ GDP on healthcare in this year.  

Performance of the public health sector in UK 

The majority of people questioned in a survey in the UK, regard the NHS as a world class health service and remain happy with the high level of care provided by the organization. Although waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.   

Among OECD member countries, the United States had the ******* percentage of gross domestic product spent on health care as of 2024. The U.S. spent nearly **** percent of its GDP on health care services. Germany, Austria, and Germany followed the U.S. with distinctly smaller percentages. The United States had both significantly higher private and public spending on health compared with other developed countries. Why compare OECD countries? OECD stands for Organization for Economic Co-operation and Development. It is an economic organization consisting of 38 members, mostly high-income countries and committed to democratic principles and market economy. This makes OECD statistics more comparable than statistics of developed and undeveloped countries. Health economics is an important matter for the OECD, even more since increasing health costs and an aging population have become an issue for many developed countries. Health costs in the U.S. A higher GDP share spent on health care does not automatically lead to a better functioning health system. In the case of the U.S., high spending is mainly because of higher costs and prices, not due to higher utilization. For example, physicians’ salaries are much higher in the U.S. than in other comparable countries. A doctor in the U.S. earns more than ***** as much as the average physician in Germany. Pharmaceutical spending per capita is also distinctly higher in the United States. Furthermore, the U.S. also spends more on health administrative costs compared to other wealthy countries.

Percentage growth and expenditure shares for public service healthcare quantity output by component.

The World Bank is a treasure trove of information. :- https://data.worldbank.org/

Generally the Gross Domestic Product of a country = the total output of the country = measure of development/total affluence of the country is measured by indicators such as household spending, government spending, level of investments etc.

Please see Bank of England explanation of GDP here :- http://edu.bankofengland.co.uk/knowledgebank/what-is-gdp/

I have argued that GDP could instead be measured better by primary indicators that lead to these what I call "secondary indicators".

Primary indicators are such as :- level of education. I hypothesize that a higher level of education leads to higher household income and hence higher household spending. So does knowing education levels of a country allow us to predict the GDP of the country?

I have used the list of primary indicators below to do a regression of the GDP per person :- (1) Women making informed choices regarding healthcare - The null hypotheses (H0)----> is the higher the level of women's education - the higher the level of national education and lesser infant mortality rates(which might be a stretch) and hence higher household income --> higher household spending ---> higher GDP. (2) Rural Population % - The null hypotheses (H0) is -----> higher rural population ----> lower per capita household income----> lower level of household spending----> lower GDP. (3) Ratio of Population having education ----> similar to above. You get the point hopefully by now... if not read a introductory macroeconomics textbook or course like this :- https://www.edx.org/course/introduction-economics-macroeconomics-snux-snu044-088-2x-0 (4) Legal Rights Strength Index-----> This actually comes from Islam. In Islam - the affluence of a country is related to truthfulness, rule of law being abided in the country etc.. For those who can understand Urdu/Hindi - please watch this video :- https://www.youtube.com/watch?v=XLjicUv0KYs (5) Credit to Private Sector -----> easier it is to open a business, work on ideas-----> higher should be the output of the country (6) Births attended by Skilled Staff ------> less infant mortality ----> indicates higher level of education and health care in the country ------> can indicate higher government spending among other factors ------>and should translate to higher level of GDP. (6) ATMMachines Ratio per 1000 people ---------> Higher level -----> shows finance is easily available -----> institutions are developed -----> maybe even indicates better public infrastructure-----> should indicate higher personal and government funding. (7) Agricultural Machines per hectare of land ------> higher automation -----> better access to finance for rural areas ------> should lead to higher GDP. (8) Literacy Rate Adults -----> the higher level of education in adults ----> higher private spending -----> should lead to higher GDP. (9) Accounts Ratio Financial Institutions -----> how many people have bank accounts who are male and over 15 ------> shows level of private spending-----> level of finance and infrastructure and hence government funding maybe -----> higher GDP.

Saudi Arabia’s Vision 2030 aims to reform health care across the Kingdom, with health technology assessment being adopted as one tool promising to improve the efficiency with which resources are used. An understanding of the opportunity costs of reimbursement decisions is key to fulfilling this promise and can be used to inform a cost-effectiveness threshold. This paper is the first to provide a range of estimates of this using existing evidence extrapolated to the context of Saudi Arabia. We use four approaches to estimate the marginal cost per unit of health produced by the healthcare system; drawing from existing evidence provided by a cross-country analysis, two alternative estimates from the UK context, and based on extrapolating a UK estimate using evidence on the income elasticity of the value of health. Consequences of estimation error are explored. Based on the four approaches, we find a range of SAR 42,046 per QALY gained (48% of GDP per capita) to SAR 215,120 per QALY gained (246% of GDP per capita). Calculated potential central estimates from the average of estimated health gains based on each source gives a range of SAR 50,000–75,000. The results are in line with estimates from the emerging literature from across the world. A cost-effectiveness threshold reflecting health opportunity costs can aid decision-making. Applying a cost-effectiveness threshold based on the range SAR 50,000 to 75,000 per QALY gained would ensure that resource allocation decisions in healthcare can in be informed in a way that accounts for health opportunity costs. A limitation is that it is not based on a within-country study for Saudi Arabia, which represents a promising line of future work. Healthcare in Saudi Arabia is undergoing wide-ranging reform through Saudi Arabia’s Vision 2030. One aim of these reforms is to ensure that money spent on healthcare generates the most improvement in population health possible. To do this requires understanding the trade-offs that exist: funding one pharmaceutical drug means that same money is not available to fund another pharmaceutical drug. This is relevant whether the new drug would be funded from within the existing budget for healthcare or from an expansion of it. If the drugs apply to the same patient population and have the same price, the question is simply, “which one generates more health?” In reality, we need to compare pharmaceutical drugs for different diseases, patient populations, and at a range of potential prices to understand whether the drug in question would generate more health per riyal spent than what is currently funded by the healthcare system. This paper provides the first estimates of the amount of health, measured in terms of quality adjusted life years (QALYs), generated by the Saudi Arabian healthcare system. We find that the healthcare system generates health at a rate of one QALY produced for every 50,000–75,000 riyals spent (58–86% of GDP per capita). Using the range we estimate to inform cost-effectiveness threshold can aid decision-making.

This statistic displays the forecast public spending on health as a percentage of GDP in the United Kingdom (UK) from 2015/16 to 2020/21. Public spending on health as a share of GDP is expected to drop to *** percent by 2020/21.

The total expenditure on health as a share of gross domestic product (GDP) in Ireland amounted to just *** percent in 2023, an increase from the previous year. Between 2009 and 2013, spending on health in Ireland was over ten percent of its GDP before declining again since 2014. Health expenditure in Ireland compared to Europe In comparison to other European countries in 2022, Ireland ranked considerably low in terms of health spending as a share of GDP. At the top of the list was Germany, which spent **** percent of its GDP on healthcare in this year.  The UK, Ireland’s closest neighbor, spent **** percent of its GDP on health. Trend of healthcare workers in Ireland In 2022, there were over **** thousand individuals employed at hospitals in Ireland, since the year 2000 this figure has increased by nearly ** thousand. Similarly, in the period since 2000, the number of general practitioners in Ireland has more than doubled to some *** thousand in 2021.

This statistic displays the projected public expenditure on healthcare as a share of GDP in the United Kingdom from 2016 to 2070. Spending on healthcare is expected to increase to *** percent share of GDP in 2070.

Snapshot img

Predictive Presymptomatic Testing Market Size 2024-2028

The predictive presymptomatic testing market size is forecast to increase by USD 2.59 billion, at a CAGR of 10.03% between 2023 and 2028. The global Predictive Presymptomatic Testing market is experiencing significant growth due to several key factors. Firstly, the increasing healthcare spending worldwide is driving demand for advanced diagnostic tools and genetic testing. Secondly, the rise in awareness toward early screening of genetic disorders has led to an increasing demand for predictive presymptomatic testing. This testing allows individuals with a family history of certain genetic disorders to identify their risk and take preventative measures before symptoms appear. Genetic counseling plays a crucial role in this process, providing essential information and support to individuals and families. As a result, the market for predictive presymptomatic testing is expected to grow steadily in the coming years.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic

In the realm of wearable technology, wrist watches and jewelry have evolved beyond mere accessories into functional devices that monitor health risks and track sleep patterns. Innovations like augmented reality and virtual reality are reshaping how we interact with information and environments, enhancing experiences through speech recognition and immersive visuals. Devices such as Google Glass integrate seamlessly into daily life, offering real-time data and enhancing safety with features like camera integration for recording events. For active lifestyles, wearables like heart rate monitors and shoes equipped with sensors provide insights into exercise intensity and performance. The development of coexistence testing ensures these technologies work harmoniously without interference, akin to how pigeons navigate without colliding in crowded skies. From tracking steps to enhancing productivity, wearable technology continues to blur the lines between fashion and functionality, promising a future where innovation meets everyday convenience.

Key Market Driver

The increasing healthcare spending worldwide is one of the key drivers supporting the predictive presymptomatic testing market growth. The governments of developed nations such as the US, Germany, and others have increased their healthcare expenditure in recent years. Through the support of the governments and a surge in healthcare expenditures, global private and public healthcare facilities and not-for-profit organizations (NPOs) are able to provide their services to patients. According to The World Health Organization (WHO), global spending on healthcare continually rose between 2000 and 2018 and reached USD 8.3 trillion or 10% of global GDP. Thus, the increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will boost the growth of the global predictive presymptomatic testing market during the forecast period.

Significant Market Trends

The growing prevalence of genetic diseases is one of the key predictive presymptomatic testing market trends that is contributing to the market growth. According to the Centers for Disease Control and Prevention (CDC), in the US, more than 1.6 million patients are getting diagnosed with cancer every year, with almost 600,000 fatalities. The incidence of genetic disorders is gradually increasing. Moreover, the increasing incidence of chronic diseases and genetic disorders leads researchers and scientists to opt for predictive presymptomatic testing for diagnosing and treating patients. Researchers are increasingly focusing on predictive presymptomatic testing due to its high impact on diagnosing and treating diseases using gene therapy and recombinant vaccines. Hence, an increase in the prevalence of genetic disorders is expected to drive the growth of the global predictive presymptomatic testing market during the forecast period.

Major Market Challenge

The high cost of tests is one of the factors hindering the predictive presymptomatic testing market growth. For instance, in 2019, the per capita healthcare expenditure was USD 7,138 in Switzerland, USD 6,748 in Norway, and USD 6,731 in Germany. Additionally, in developing countries such as India, China, and others, due to a lack of resources and low per capita income, patients are unable to avail themselves of predictive presymptomatic test kits. The absence of proper healthcare infrastructure and less amount of government aid received in the form of medical expense reimbursement further acts as a challenge for the patients in these countries. Thus, the global per capita healthcare cost is expected to increase during the forecast period. This will negatively affect the growth of the global predictive presymptomatic testing market during the forecast period.

Ex

Public service healthcare inputs, output and productivity series for England on a financial year basis.

In 2024, the United States had the ******* per capita health expenditure among OECD countries. At that time, per capita health expenditure in the U.S. amounted over ******** U.S. dollars, significantly higher than in Switzerland, the country with the ************** per capita health expenditure. Norway, Germany and, the Netherlands are also within the top five countries with the highest per capita health expenditure. The United States also spent the highest share of it’s gross domestic product on health care, with **** percent of its GDP spent on health care services. Health Expenditure in the U.S. The United States is the highest spending country worldwide when it comes to health care. In 2023, total health expenditure in the U.S. came close to **** trillion dollars. Expenditure as a percentage of GDP is projected to increase to approximately ** percent by the year 2033. Distribution of Health Expenditure in the U.S. Health expenditure in the United States is spread out across multiple categories such as nursing home facilities, home health care, and prescription drugs. As of 2023, the majority of health expenditure in the United States was spent on hospital care, accounting for a bit less than *** third of all health spending. Hospital care was followed by spending on physician and clinical services which accounted for ** percent of overall health expenditure.

Health care spending in Turkey as a share of the gross domestic product (GDP) amounted to **** percent in 2022, which was the lowest figure recorded throughout the observed period. In the years 2007 to 2009, health care spending peaked at *** percent of GDP in Turkey but has fallen since then.

Health expenditure compared to Europe 

In comparison to other European countries in 2022, Turkey was at the bottom of the ranking in terms of health care spending as a share of the GDP. Top of the list was Germany, which spent **** percent of its’ GDP on health care in this year. While France and the United Kingdom both spent about ** percent on health. 

Interactions with the health system in Turkey

In 2022, roughly *** in ten individuals had visited a general practitioner in the past 12 months, women were more likely than men to do so. Furthermore, a 2023 study found that ** percent of those surveyed rated the quality of health care in Turkey as good, compared to ** percent who rated it as poor.